chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 1.0
Sex: M
Vaccine: MMR, VARCEL
Symptoms: Irritability, Rash erythematous, Sluggishness, Urticaria
Clinical narrative: On 11/21/2018, client was very fussy and sluggish, then on 11/22/2018 client was covered with hives (red bumps) all over both legs, stomach and face. However there was no fever.
Age: 79.0
Sex: F
Vaccine: VARZOS
Symptoms: Oral pain, Tongue disorder
Clinical narrative: 11/16/18: patient received the vaccine. 11/17/18: Patient reported bumps on the tongue. 11/18/18: Patient reported "cottage cheese" covered top of tongue. 11/19-20/18: Patient was given an Rx from the doctor for a version of Magic Mouthwash. Now the patient reports that the mouth is less painful and only half covered. May have had a slight fever on 11/21/18.
Age: 54.0
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Fatigue, Feeling of body temperature change, Headache, Nausea
Clinical narrative: Severe all over body aches, extreme fatigue, shivering, shakiness, headache, suspected fever, fluctuating between hot and cold, nausea.
Age: 54.0
Sex: F
Vaccine: VARZOS
Symptoms: Pain, Pyrexia, Tremor
Clinical narrative: Severe all over body aches, extreme fatigue, shivering, shakiness, headache, suspected fever, fluctuating between hot and cold, nausea.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On an unspecified date in 2016, the patient was vaccinated with ZOSTAVAX (strength, dose, route, anatomical location, lot number and expiration date were not reported), to obtain permanent prevention and protection against shingles and zoster-related injuries as recommended by the healthcare professional. On or about 07-JAN-2017, the patient experienced shingles and was treated by a physician at a hospital. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX and suffered serious physical, emotional, and economic damages, as a result of patient's injuries on unknown dates. The patient had and would continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs included care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. At the time of the report, the patient was not recovered from emotional distress and pain, and the outcome of the patient regarding the vaccination failure, herpes zoster, quality of life decreased and the pre-existing unspecified conditions aggravated was unknown. The relatedness between ZOSTAVAX and the aforementioned events was assessed as related by the reporter. The reporter determined all the events to be serious due to disability, life-threatening and medically significant.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On 11-MAY-2012, the patient was inoculated with ZOSTAVAX at a Clinic for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster. On 13-OCT-2016, the patient was treated by a healthcare professional and was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life, increased risk of premature death, aggravation of pre-existing conditions and activation of latent conditions; lost wages; loss of earnings capacity, and other losses and damages and pain and suffering, and other damages. At the time of the report, the outcome of the aforementioned adverse events was unknown, excepting for the events of emotional distress and pain that was reported as not resolved. The relatedness assessment between the aforementioned adverse events and ZOSTAVAX was related. The reporter considered the events as serious for the following reasons: Hospitalization, life-threatening, disability and medical significant.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On an unspecified date in 2016, the patient was vaccinated with ZOSTAVAX (strength, dose, route, anatomical location, lot number and expiration date were not reported), to obtain permanent prevention and protection against shingles and zoster-related injuries (prophylaxis) as recommended by the healthcare professional (unspecified). On an unspecified date in 2016, the patient experienced shingles (herpes zoster) and was treated by a healthcare provider (unspecified). The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX (vaccination failure) and suffered serious physical, emotional, and economic damages (emotional distress), as a result of patient's injuries on unknown dates. The patient had and would continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering (emotional distress, pain); extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs included care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (condition aggravated); lost wages; loss of earnings capacity; and other losses and damages. At the time of the report, the patient was not recovered from emotional distress and pain, and the outcome of the patient regarding the vaccination failure, herpes zoster, quality of life decreased and the pre-existing unspecified conditions aggravated was unknown. The relatedness between ZOSTAVAX and the aforementioned events was assessed as related by the reporter. The reporter determined all the events to be serious due to disability, life-threatening and medically significant.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Information has been received regarding a case in litigation from a lawyer and refers to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, drug reactions or allergies were not reported. On an unknown date in 2014, the patient was vaccinated with ZOSTAVAX, (strength, route, anatomical location, dose, frequency, dose number, lot number and expiration date were not reported), for the permanent prevention and protection against shingles and zoster-related conditions/injuries (prophylaxis). No other suspect or concomitant therapies were reported. On an unknown date, the patient was diagnosed with shingles (herpes zoster) and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX (vaccination failure), and suffered serious physical, emotional, and economic damages as a result. In addition, the patient would continue to suffer ongoing injuries, included but not limited to: mental and physical pain and suffering (Emotional distress and pain), extensive medical care and treatment for these injuries, significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications and supplies; diminished capacity for the enjoyment of life; diminished quality of life (Quality of life decreased); increased risk of premature death, aggravation of pre-existing conditions and activations of laten conditions (Condition aggravated), lost wages, loss of earning capacity and other losses and damages. On an unknown date in 2016, the patient was treated for shingles. At the time of report, the patient was not recovered from emotional distress and pain, and the outcome of the patient regarding the vaccination failure, herpes zoster, quality of life decreased and the pre-existing unspecified conditions aggravated was unknown. The reporter considered all aforementioned adverse events to be related to ZOSTAVAX. The reporter determined the adverse events as medically significant, disabling and life-threatening events.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Information has been received regarding a case in litigation from a lawyer and refers to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, drug reactions or allergies were not reported. On approximately 04-OCT-2011 (reported as on or about 04-OCT-2011), the patient was vaccinated with ZOSTAVAX, (strength, route, anatomical location, dose, frequency, dose number, lot number and expiration date were not reported), for the permanent prevention and protection against shingles and zoster-related conditions/injuries (prophylaxis). No other suspect or concomitant therapies were reported. On an unknown date, the patient was diagnosed with shingles (herpes zoster) and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX (vaccination failure), and suffered serious physical, emotional, and economic damages as a result. In addition, the patient would continue to suffer ongoing injuries, included but not limited to: mental and physical pain and suffering (Emotional distress and pain), extensive medical care and treatment for these injuries, significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications and supplies; diminished capacity for the enjoyment of life; diminished quality of life (Quality of life decreased); increased risk of premature death, aggravation of pre-existing conditions and activations of laten conditions (Condition aggravated), lost wages, loss of earning capacity and other losses and damages. On an unknown date in 2015, the patient was treated for shingles. At the time of report, the patient was not recovered from emotional distress and pain, and the outcome of the patient regarding the vaccination failure, herpes zoster, quality of life decreased and the pre-existing unspecified conditions aggravated was unknown. The reporter considered all aforementioned adverse events to be related to ZOSTAVAX. The reporter determined adverse events as medically significant, disabling and life-threatening events.
Age: 1.25
Sex: F
Vaccine: DTAP, FLU4, MMR, VARCEL
Symptoms: Pyrexia, Rash
Clinical narrative: Rash, low grade fever 100.0 F.
Age: 2.0
Sex: M
Vaccine: DTAP
Symptoms: Gait disturbance, Injection site bruising, Injection site pain, Injection site swelling, Peripheral swelling
Clinical narrative: Entire limb swelling within hours of vaccine. Tenderness, swelling, bruising at site, limping for 7 days following vaccine.
Age: 86.0
Sex: F
Vaccine: FLUA3
Symptoms: Injection site pain, Loss of personal independence in daily activities
Clinical narrative: Right arm pain from shoulder to elbow limiting ADLs due to pain. Being treated with heat, ice, stretches. Ongoing for 2 months since injection, waxing/waning but not improving overall.
Age: 93.0
Sex: M
Vaccine: FLU3
Symptoms: Dyspnoea, Swelling, Swelling face, Throat tightness
Clinical narrative: Based on phone call from daughter (who had the same symptoms), about 8 hours after the immunization at around 12 AM he began to have swelling of the face and neck, sensation of throat closing, and some trouble breathing. They went to the emergency room and he was treated, watched, and then sent home.
Age: 59.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Chills, Injection site erythema, Injection site pain, Injection site warmth
Clinical narrative: Erythema, tenderness, and warm to touch at injection site, fever, chills, joint pain.
Age: 59.0
Sex: F
Vaccine: VARZOS
Symptoms: Pyrexia
Clinical narrative: Erythema, tenderness, and warm to touch at injection site, fever, chills, joint pain.
Age: 67.0
Sex: F
Vaccine: FLU3
Symptoms: Swelling face
Clinical narrative: She, along with her elderly father, around 8 hours after the immunization, experienced swelling of the face and neck. She took her father to the emergency room as his symptoms were similar, but more severe. She was not treated, waited for her father, then both went home.
Age: 69.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Blister, Decreased activity, Pain in extremity, Sleep disorder
Clinical narrative: Pain in left arm starting 10 days after injection but not at injection site; pain disrupted activity and sleep; blisters on left arm but not at site of injection; CRNP prescribed CIPRO 250mg two times a day for 7 days.
Age: 69.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Blister, Injection site erythema, Pain in extremity
Clinical narrative: Pain in left arm starting 10 days after injection but not at injection site; pain disrupted activity and sleep; blisters on left arm but not at site of injection; CRNP prescribed CIPRO 250mg two times a day for 7 days.
Age: 43.0
Sex: F
Vaccine: HEPA, HEPA
Symptoms: Hypoaesthesia, Injection site hypoaesthesia, Injection site paraesthesia, Paraesthesia
Clinical narrative: NUMBNESS/TINGLING STARTING AT THE INJECTION SITE AND TRAVELING DOWN THE ARM TO THE HAND. STARTED WITHIN 2 MINUTES OF VACCINATION INJECTION.
Age: 43.0
Sex: F
Vaccine: HEPA, HEPA
Symptoms: Burning sensation, Hypoaesthesia, Joint range of motion decreased, Paraesthesia
Clinical narrative: NUMBNESS/TINGLING STARTING AT THE INJECTION SITE AND TRAVELING DOWN THE ARM TO THE HAND. STARTED WITHIN 2 MINUTES OF VACCINATION INJECTION.
Age: 1.0
Sex: F
Vaccine: FLU4, HEPA, MMR, VARCEL
Symptoms: Febrile convulsion, Irritability, Pallor, Rash macular, Rash morbilliform
Clinical narrative: Seen on 11/23/18 for febrile seizure in CHO Seen on 11/26/18 for macular, blanching rash on arms, trunk, and back - similar to measles rash + fussiness.
Age: 67.0
Sex: F
Vaccine: FLU3, PPV
Symptoms: Injection site pain
Clinical narrative: Family MD called to report seeing pt today for F/U from ER visit on 10/22/18 after pt received FLUZONE HD and PSV23 at our pharmacy. Pt's reported pain level at ER was "20 on scale 1-10."  Per pt, she has had 3 subsequent courses of NSAIDS/steroids trying to relieve pain from injection site. "Was in tremendous pain X 1 month, tolerable now but still has some pain." Pt is getting MRI scheduled.
Age: 45.0
Sex: F
Vaccine: FLU4
Symptoms: Dizziness, Dyspnoea
Clinical narrative: Patient reported feeling dizzy, then trouble breathing (shortness of breath) later at night, as well as light-headed.
Age: 65.0
Sex: M
Vaccine: VARZOS
Symptoms: Dizziness
Clinical narrative: Patient complained of feeling very lightheaded and dizzy, he was sitting down when vaccination was given, but then stood up to go to register which was a couple of steps away. Reaction occured within 2-3 minutes of administration. Advised patient to have a seat, set a timer for 15 minutes while seated. Blood pressure was taken by pharmacist, results were 140/85, patient added that was his normal range on a daily basis. As the 15 minutes passed, his lightheadedness decreased but not 100%. His wife was present, and drove him home. Called patient next morning 11/26/18 around 9:45am, patient confirms feeling 100% and the reaction was just at the pharmacy.
Age: 10.0
Sex: M
Vaccine: FLUX
Symptoms: Adverse reaction
Clinical narrative: The vaccination was not given by our facility. The patient's parent reported that the patient had been given the influenza vaccine by his PCP. The parents brought him to our facility, D/T concern for possible reaction. I do not have access to the documentation for the vaccine that was given, only the verbal report from parent.
Age: 61.0
Sex: F
Vaccine: VARZOS
Symptoms: Loss of personal independence in daily activities, Myalgia, Nausea, Pyrexia
Clinical narrative: Fever, Muscle aches, Extreme nausea, Unable to function as normal.
Age: 0.58
Sex: F
Vaccine: DTAPIPVHIB, PNC13, RV5
Symptoms: Apallic syndrome, Computerised tomogram normal, Metabolic function test normal, Mobility decreased, Nuclear magnetic resonance imaging normal
Clinical narrative: My daughter was meeting a few of her milestones like rolling over, holding her head, swatting at toys and her eye track was great. The day of the vaccines I told her pediatrician she had a cold and to hold off on thee vaccines. She had goopy eyes and sniffles. The doctor said the vaccine would not affect her at all so we went ahead and got her the vaccines. Trusting my pediatrician knew what she was doing. My daughter at the time was 19 lbs she is now almost 4 and we struggle to keep her at 26lbs. The day of the vaccine she began shaking at night so I took her to the ER and was told she had a seizure. I have records of all this. She stopped moving her limbs, did not track and was basically in a vegetative state. She lost weight so I took her to many specialists after.
Age: 0.58
Sex: F
Vaccine: DTAPIPVHIB, PNC13, RV5
Symptoms: Seizure, Tremor, Weight decreased, Weight gain poor
Clinical narrative: My daughter was meeting a few of her milestones like rolling over, holding her head, swatting at toys and her eye track was great. The day of the vaccines I told her pediatrician she had a cold and to hold off on thee vaccines. She had goopy eyes and sniffles. The doctor said the vaccine would not affect her at all so we went ahead and got her the vaccines. Trusting my pediatrician knew what she was doing. My daughter at the time was 19 lbs she is now almost 4 and we struggle to keep her at 26lbs. The day of the vaccine she began shaking at night so I took her to the ER and was told she had a seizure. I have records of all this. She stopped moving her limbs, did not track and was basically in a vegetative state. She lost weight so I took her to many specialists after.
Age: 38.0
Sex: F
Vaccine: FLU3
Symptoms: Blood test, Fatigue, Narcolepsy, Nuclear magnetic resonance imaging, Sleep study
Clinical narrative: I was diagnosed with Narcolepsy 5/2018. I am now on daily medication to treat this. Modafinil and ADDERALL. I have documentation of flu vaccines I have recieved since 2011. Due to the nature of my diagnosis, I am unable to determine which, if any of those vaccines were responsible. I know that GlaxoSmithKine had a vaccine in 2009-2010 that was responsible for the development of narcolepsy in some patients over seas.  And I am suspicious that I have also been affected by an ingredient used. 2012-Lot #AFLUA716BA; 2013-Lot# 35SN5; 2014-Novartis 160984; 2015-Novartis 713906; 2016 FLUCELVAX 185887; 2017 ?; 2018 Lot # YT38507A. The facility I work for mandates annual flu vaccines. I think it is kind of significant that 3 nurses in my department have been diagnosed with Narcolepsy in the last year.
Age: 67.0
Sex: F
Vaccine: FLU3, PPV
Symptoms: Back pain, Dyspnoea, Muscle spasms
Clinical narrative: 5 minutes after vaccine administration, pt reported back spasms and pain, also felt difficulty breathing. Pt went home to rest.
Age: 50.0
Sex: M
Vaccine: FLUC4
Symptoms: Injection site erythema, Injection site induration, Injection site pain, Injection site pustule, Injection site warmth
Clinical narrative: Patient's upper arm around the injection site is red and pus-like. Pt reports hotness and pain around the area, as well as hardening of the skin around injection site.
Age: 24.0
Sex: F
Vaccine: FLU4
Symptoms: Cough, Dyspnoea, Generalised erythema, Throat tightness
Clinical narrative: Patient received her flu vaccine at the flu clinic and within a minute, patient started with a dry cough then complained of shortness of breath and was extremely red all over. Patient complained that her throat was starting to close up. Patient was administered 50 mg BENADRYL IM and EMS called. Continued to monitor patient who stated she was starting to feel better within a few minutes after receiving BENADRYL. EMS arrived and monitored for 30 minutes. Patient signed AMA not going to hospital and EMS left clinic. RN continued to monitor patient until patient's husband picked her up an hour later.
Age: 70.0
Sex: M
Vaccine: PPV, VARCEL
Symptoms: Erythema, Injection site erythema, Injection site hypersensitivity, Injection site pallor, Injection site swelling
Clinical narrative: On 9-13-18 patient received PNEUMOVAX in the L deltoid, and V Zoster vaccination in the R deltoid. Pt. has had progressive swelling in the L arm since this began on the evening after the injections. Large white urticarial lesion over injection site L deltoid, redness and swelling over 1/2 of remaining upper arm, and onto L lateral chest wall. Allergic reaction to PNEUMOVAX.
Age: 70.0
Sex: M
Vaccine: PPV, VARCEL
Symptoms: Injection site urticaria, Peripheral swelling, Swelling
Clinical narrative: On 9-13-18 patient received PNEUMOVAX in the L deltoid, and V Zoster vaccination in the R deltoid. Pt. has had progressive swelling in the L arm since this began on the evening after the injections. Large white urticarial lesion over injection site L deltoid, redness and swelling over 1/2 of remaining upper arm, and onto L lateral chest wall. Allergic reaction to PNEUMOVAX.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Autoimmune disorder, Autoinflammatory disease, Biopsy bone marrow
Clinical narrative: Pt spiked fevers day after vaccines. Admitted to hospital after 5 days of fever. Bone marrow done. Pt pancytopenic. No source of fever found. Bone marrow eventually recovered. Patient had bone marrow biopsy, EEG (Febrile seizure), brain MRI, abdominal CT scan, CXR. Oncology, rheumatology and infectious disease consults. Multiple viral swabs negative. CRP elevated to 15. Typhus fever neg. Rickettsial serology negative. Epstein-Barr virus AB panel done - suggestive of a past EBV infection. Moderate lymphopenia, she was treated for a tick borne illness - Doxycycline (9/9/18). D/C Dx systemic inflammatory process of indeterminate etiology, suspect autoimmune vs autoinflammatory vs infectious, pancytopenia which was resolved, thrombocytosis (suspect reactive), Hepatitis, lipemia of indeterminate etiology, and paroxysmal spell, non-epileptiform. At arrival to hospital a lab work up was done and was notable for elevated transaminase (AST 210, ALT 144), elevated ESR 144. Positive rhinovirus. Admitted initially for dehydration on 9/6/18. Patient was discharged on 9/14/18. Patient followed up with Cardio for an Echo, indicated Kawasaki's syndrome (9/21/18).
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: C-reactive protein increased, Chest X-ray, Computerised tomogram abdomen, Dehydration, Echocardiogram abnormal
Clinical narrative: Pt spiked fevers day after vaccines. Admitted to hospital after 5 days of fever. Bone marrow done. Pt pancytopenic. No source of fever found. Bone marrow eventually recovered. Patient had bone marrow biopsy, EEG (Febrile seizure), brain MRI, abdominal CT scan, CXR. Oncology, rheumatology and infectious disease consults. Multiple viral swabs negative. CRP elevated to 15. Typhus fever neg. Rickettsial serology negative. Epstein-Barr virus AB panel done - suggestive of a past EBV infection. Moderate lymphopenia, she was treated for a tick borne illness - Doxycycline (9/9/18). D/C Dx systemic inflammatory process of indeterminate etiology, suspect autoimmune vs autoinflammatory vs infectious, pancytopenia which was resolved, thrombocytosis (suspect reactive), Hepatitis, lipemia of indeterminate etiology, and paroxysmal spell, non-epileptiform. At arrival to hospital a lab work up was done and was notable for elevated transaminase (AST 210, ALT 144), elevated ESR 144. Positive rhinovirus. Admitted initially for dehydration on 9/6/18. Patient was discharged on 9/14/18. Patient followed up with Cardio for an Echo, indicated Kawasaki's syndrome (9/21/18).
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Electroencephalogram abnormal, Epstein-Barr virus antibody positive, Febrile convulsion, Hepatitis, Human rhinovirus test positive
Clinical narrative: Pt spiked fevers day after vaccines. Admitted to hospital after 5 days of fever. Bone marrow done. Pt pancytopenic. No source of fever found. Bone marrow eventually recovered. Patient had bone marrow biopsy, EEG (Febrile seizure), brain MRI, abdominal CT scan, CXR. Oncology, rheumatology and infectious disease consults. Multiple viral swabs negative. CRP elevated to 15. Typhus fever neg. Rickettsial serology negative. Epstein-Barr virus AB panel done - suggestive of a past EBV infection. Moderate lymphopenia, she was treated for a tick borne illness - Doxycycline (9/9/18). D/C Dx systemic inflammatory process of indeterminate etiology, suspect autoimmune vs autoinflammatory vs infectious, pancytopenia which was resolved, thrombocytosis (suspect reactive), Hepatitis, lipemia of indeterminate etiology, and paroxysmal spell, non-epileptiform. At arrival to hospital a lab work up was done and was notable for elevated transaminase (AST 210, ALT 144), elevated ESR 144. Positive rhinovirus. Admitted initially for dehydration on 9/6/18. Patient was discharged on 9/14/18. Patient followed up with Cardio for an Echo, indicated Kawasaki's syndrome (9/21/18).
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Hyperlipidaemia, Infection, Kawasaki's disease, Laboratory test normal, Lymphopenia
Clinical narrative: Pt spiked fevers day after vaccines. Admitted to hospital after 5 days of fever. Bone marrow done. Pt pancytopenic. No source of fever found. Bone marrow eventually recovered. Patient had bone marrow biopsy, EEG (Febrile seizure), brain MRI, abdominal CT scan, CXR. Oncology, rheumatology and infectious disease consults. Multiple viral swabs negative. CRP elevated to 15. Typhus fever neg. Rickettsial serology negative. Epstein-Barr virus AB panel done - suggestive of a past EBV infection. Moderate lymphopenia, she was treated for a tick borne illness - Doxycycline (9/9/18). D/C Dx systemic inflammatory process of indeterminate etiology, suspect autoimmune vs autoinflammatory vs infectious, pancytopenia which was resolved, thrombocytosis (suspect reactive), Hepatitis, lipemia of indeterminate etiology, and paroxysmal spell, non-epileptiform. At arrival to hospital a lab work up was done and was notable for elevated transaminase (AST 210, ALT 144), elevated ESR 144. Positive rhinovirus. Admitted initially for dehydration on 9/6/18. Patient was discharged on 9/14/18. Patient followed up with Cardio for an Echo, indicated Kawasaki's syndrome (9/21/18).
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Nuclear magnetic resonance imaging brain, Pancytopenia, Pyrexia, Red blood cell sedimentation rate increased, Serology negative
Clinical narrative: Pt spiked fevers day after vaccines. Admitted to hospital after 5 days of fever. Bone marrow done. Pt pancytopenic. No source of fever found. Bone marrow eventually recovered. Patient had bone marrow biopsy, EEG (Febrile seizure), brain MRI, abdominal CT scan, CXR. Oncology, rheumatology and infectious disease consults. Multiple viral swabs negative. CRP elevated to 15. Typhus fever neg. Rickettsial serology negative. Epstein-Barr virus AB panel done - suggestive of a past EBV infection. Moderate lymphopenia, she was treated for a tick borne illness - Doxycycline (9/9/18). D/C Dx systemic inflammatory process of indeterminate etiology, suspect autoimmune vs autoinflammatory vs infectious, pancytopenia which was resolved, thrombocytosis (suspect reactive), Hepatitis, lipemia of indeterminate etiology, and paroxysmal spell, non-epileptiform. At arrival to hospital a lab work up was done and was notable for elevated transaminase (AST 210, ALT 144), elevated ESR 144. Positive rhinovirus. Admitted initially for dehydration on 9/6/18. Patient was discharged on 9/14/18. Patient followed up with Cardio for an Echo, indicated Kawasaki's syndrome (9/21/18).
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Systemic inflammatory response syndrome, Thrombocytosis, Typhus rickettsia test, Viral test negative
Clinical narrative: Pt spiked fevers day after vaccines. Admitted to hospital after 5 days of fever. Bone marrow done. Pt pancytopenic. No source of fever found. Bone marrow eventually recovered. Patient had bone marrow biopsy, EEG (Febrile seizure), brain MRI, abdominal CT scan, CXR. Oncology, rheumatology and infectious disease consults. Multiple viral swabs negative. CRP elevated to 15. Typhus fever neg. Rickettsial serology negative. Epstein-Barr virus AB panel done - suggestive of a past EBV infection. Moderate lymphopenia, she was treated for a tick borne illness - Doxycycline (9/9/18). D/C Dx systemic inflammatory process of indeterminate etiology, suspect autoimmune vs autoinflammatory vs infectious, pancytopenia which was resolved, thrombocytosis (suspect reactive), Hepatitis, lipemia of indeterminate etiology, and paroxysmal spell, non-epileptiform. At arrival to hospital a lab work up was done and was notable for elevated transaminase (AST 210, ALT 144), elevated ESR 144. Positive rhinovirus. Admitted initially for dehydration on 9/6/18. Patient was discharged on 9/14/18. Patient followed up with Cardio for an Echo, indicated Kawasaki's syndrome (9/21/18).
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Activated partial thromboplastin time, Blood culture, Blood immunoglobulin A, Blood immunoglobulin E, Blood immunoglobulin G
Clinical narrative: Patient presented to ER on 7/1/18 with increasing ecchymoses and petechiae. She was transferred to PICU for severe thrombocytopenia with platelet count of 1K. She received 2 doses of IVIG 1 g/kg and 1 dose of SOLU-MEDROL 4mg/kg, stabilizing and improving platelets to 65K on 7/4/18. She developed fever of 104.8 on day 2 of hospital stay, 5 hours after receiving 2nd dose of IVIG. She was given 1 dose of ROCEPHIN IV. Patient was diagnosed with neutropenia on 7/4/18 and was discharged after discussion with hematology. She followed up with PCP on 7/5/18.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Blood immunoglobulin M, C-reactive protein, Ecchymosis, Full blood count, Immunoglobulin therapy
Clinical narrative: Patient presented to ER on 7/1/18 with increasing ecchymoses and petechiae. She was transferred to PICU for severe thrombocytopenia with platelet count of 1K. She received 2 doses of IVIG 1 g/kg and 1 dose of SOLU-MEDROL 4mg/kg, stabilizing and improving platelets to 65K on 7/4/18. She developed fever of 104.8 on day 2 of hospital stay, 5 hours after receiving 2nd dose of IVIG. She was given 1 dose of ROCEPHIN IV. Patient was diagnosed with neutropenia on 7/4/18 and was discharged after discussion with hematology. She followed up with PCP on 7/5/18.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Intensive care, Laboratory test, Metabolic function test, Neutropenia, Petechiae
Clinical narrative: Patient presented to ER on 7/1/18 with increasing ecchymoses and petechiae. She was transferred to PICU for severe thrombocytopenia with platelet count of 1K. She received 2 doses of IVIG 1 g/kg and 1 dose of SOLU-MEDROL 4mg/kg, stabilizing and improving platelets to 65K on 7/4/18. She developed fever of 104.8 on day 2 of hospital stay, 5 hours after receiving 2nd dose of IVIG. She was given 1 dose of ROCEPHIN IV. Patient was diagnosed with neutropenia on 7/4/18 and was discharged after discussion with hematology. She followed up with PCP on 7/5/18.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Platelet count decreased, Procalcitonin, Prothrombin time, Pyrexia, Respiratory viral panel
Clinical narrative: Patient presented to ER on 7/1/18 with increasing ecchymoses and petechiae. She was transferred to PICU for severe thrombocytopenia with platelet count of 1K. She received 2 doses of IVIG 1 g/kg and 1 dose of SOLU-MEDROL 4mg/kg, stabilizing and improving platelets to 65K on 7/4/18. She developed fever of 104.8 on day 2 of hospital stay, 5 hours after receiving 2nd dose of IVIG. She was given 1 dose of ROCEPHIN IV. Patient was diagnosed with neutropenia on 7/4/18 and was discharged after discussion with hematology. She followed up with PCP on 7/5/18.
Age: 1.0
Sex: F
Vaccine: HEPA, MMR, VARCEL
Symptoms: Reticulocyte count, Staphylococcus test, Thrombocytopenia, Urine analysis
Clinical narrative: Patient presented to ER on 7/1/18 with increasing ecchymoses and petechiae. She was transferred to PICU for severe thrombocytopenia with platelet count of 1K. She received 2 doses of IVIG 1 g/kg and 1 dose of SOLU-MEDROL 4mg/kg, stabilizing and improving platelets to 65K on 7/4/18. She developed fever of 104.8 on day 2 of hospital stay, 5 hours after receiving 2nd dose of IVIG. She was given 1 dose of ROCEPHIN IV. Patient was diagnosed with neutropenia on 7/4/18 and was discharged after discussion with hematology. She followed up with PCP on 7/5/18.
Age: 42.0
Sex: F
Vaccine: FLUX
Symptoms: Acute macular outer retinopathy, Angiogram normal, Fundoscopy abnormal, Intraocular pressure test normal, Optical coherence tomography abnormal
Clinical narrative: This serious literature case, initially received on 12-Nov-2018 (combinedly processed), reported by other health professional and concerns a 42-year-old, adult, female patient. The patient had no historical condition. The patient's vaccination history included unspecified flu vaccine for an unknown indication and denied experiencing similar symptoms in the past. The patient did not use any medication including oral contraceptives and denied use of stimulants and caffeine supplements, including tea and coffee. On an unspecified date, the patient was administered Influenza virus vaccine (dose, route of administration, anatomical location, batch number, trade name, manufacturer and expiry date: not reported). On an unspecified period after vaccination, the patient had a post-vaccination prolonged viral-like illness. On an unspecified date, 3 weeks after vaccination, the patient presented with 2 weeks history of black-spot which turned green in the right eye. The patient also described the presence of paracentral scotoma. The patient denied any flashes, pain or blurred vision. On unspecified dates, the patient underwent Snellen vision acuity (VA) test which showed 20/20 with an intraocular pressure (IOP) of 12 mm Hg in the right eye and slit-lamp examination was unremarkable. Funduscopic examination revealed a slight reddish-brown petaloid lesion superonasal to the fovea. Near-infrared (SLO) imaging of the right eye revealed a wedge-shaped dark lesion superonasal to the fovea. Spectral-domain optical coherence tomography (SD-OCT) demonstrated hyperreflectivity of the outer plexiform layer (OPL), with characteristic shadowing of the ellipsoid zone. A fluorescein angiography was performed, but the findings were unremarkable and did not show signs of any other inflammatory lesions. The patient was diagnosed with acute macular neuroretinopathy (AMN) of the right eye likely secondary to the influenza vaccination and was observed for 4 weeks. On follow-up visit, 1 month later, the patient was experiencing a floater in the right eye but the improvement of the scotoma (recovering). The patient continued to deny any flashes, pain, or decline in vision. The VA in the right eye improved to 20/15 with an IOP of 19 mm Hg. Funduscopic exam no longer demonstrated a lesion. Near-infrared imaging showed interval improvement of the wedge-shaped lesion. SD-OCT showed improved hyperreflectivity of the OPL with decreased shadowing of the ellipsoid zone. At the time of this report, the patient was recovering from AMN and paracentral scotoma. The outcome of the events viral-like illness, floaters in the right eye and spots in the right eye was not reported. The reporter assessed the causality of the event AMN as related to the suspect vaccine (possibility of the influenza vaccination).
Age: 42.0
Sex: F
Vaccine: FLUX
Symptoms: Scleral discolouration, Slit-lamp tests normal, Vaccination complication, Viral infection, Visual acuity tests normal
Clinical narrative: This serious literature case, initially received on 12-Nov-2018 (combinedly processed), reported by other health professional and concerns a 42-year-old, adult, female patient. The patient had no historical condition. The patient's vaccination history included unspecified flu vaccine for an unknown indication and denied experiencing similar symptoms in the past. The patient did not use any medication including oral contraceptives and denied use of stimulants and caffeine supplements, including tea and coffee. On an unspecified date, the patient was administered Influenza virus vaccine (dose, route of administration, anatomical location, batch number, trade name, manufacturer and expiry date: not reported). On an unspecified period after vaccination, the patient had a post-vaccination prolonged viral-like illness. On an unspecified date, 3 weeks after vaccination, the patient presented with 2 weeks history of black-spot which turned green in the right eye. The patient also described the presence of paracentral scotoma. The patient denied any flashes, pain or blurred vision. On unspecified dates, the patient underwent Snellen vision acuity (VA) test which showed 20/20 with an intraocular pressure (IOP) of 12 mm Hg in the right eye and slit-lamp examination was unremarkable. Funduscopic examination revealed a slight reddish-brown petaloid lesion superonasal to the fovea. Near-infrared (SLO) imaging of the right eye revealed a wedge-shaped dark lesion superonasal to the fovea. Spectral-domain optical coherence tomography (SD-OCT) demonstrated hyperreflectivity of the outer plexiform layer (OPL), with characteristic shadowing of the ellipsoid zone. A fluorescein angiography was performed, but the findings were unremarkable and did not show signs of any other inflammatory lesions. The patient was diagnosed with acute macular neuroretinopathy (AMN) of the right eye likely secondary to the influenza vaccination and was observed for 4 weeks. On follow-up visit, 1 month later, the patient was experiencing a floater in the right eye but the improvement of the scotoma (recovering). The patient continued to deny any flashes, pain, or decline in vision. The VA in the right eye improved to 20/15 with an IOP of 19 mm Hg. Funduscopic exam no longer demonstrated a lesion. Near-infrared imaging showed interval improvement of the wedge-shaped lesion. SD-OCT showed improved hyperreflectivity of the OPL with decreased shadowing of the ellipsoid zone. At the time of this report, the patient was recovering from AMN and paracentral scotoma. The outcome of the events viral-like illness, floaters in the right eye and spots in the right eye was not reported. The reporter assessed the causality of the event AMN as related to the suspect vaccine (possibility of the influenza vaccination).
Age: 42.0
Sex: F
Vaccine: FLUX
Symptoms: Visual field defect, Vitreous floaters
Clinical narrative: This serious literature case, initially received on 12-Nov-2018 (combinedly processed), reported by other health professional and concerns a 42-year-old, adult, female patient. The patient had no historical condition. The patient's vaccination history included unspecified flu vaccine for an unknown indication and denied experiencing similar symptoms in the past. The patient did not use any medication including oral contraceptives and denied use of stimulants and caffeine supplements, including tea and coffee. On an unspecified date, the patient was administered Influenza virus vaccine (dose, route of administration, anatomical location, batch number, trade name, manufacturer and expiry date: not reported). On an unspecified period after vaccination, the patient had a post-vaccination prolonged viral-like illness. On an unspecified date, 3 weeks after vaccination, the patient presented with 2 weeks history of black-spot which turned green in the right eye. The patient also described the presence of paracentral scotoma. The patient denied any flashes, pain or blurred vision. On unspecified dates, the patient underwent Snellen vision acuity (VA) test which showed 20/20 with an intraocular pressure (IOP) of 12 mm Hg in the right eye and slit-lamp examination was unremarkable. Funduscopic examination revealed a slight reddish-brown petaloid lesion superonasal to the fovea. Near-infrared (SLO) imaging of the right eye revealed a wedge-shaped dark lesion superonasal to the fovea. Spectral-domain optical coherence tomography (SD-OCT) demonstrated hyperreflectivity of the outer plexiform layer (OPL), with characteristic shadowing of the ellipsoid zone. A fluorescein angiography was performed, but the findings were unremarkable and did not show signs of any other inflammatory lesions. The patient was diagnosed with acute macular neuroretinopathy (AMN) of the right eye likely secondary to the influenza vaccination and was observed for 4 weeks. On follow-up visit, 1 month later, the patient was experiencing a floater in the right eye but the improvement of the scotoma (recovering). The patient continued to deny any flashes, pain, or decline in vision. The VA in the right eye improved to 20/15 with an IOP of 19 mm Hg. Funduscopic exam no longer demonstrated a lesion. Near-infrared imaging showed interval improvement of the wedge-shaped lesion. SD-OCT showed improved hyperreflectivity of the OPL with decreased shadowing of the ellipsoid zone. At the time of this report, the patient was recovering from AMN and paracentral scotoma. The outcome of the events viral-like illness, floaters in the right eye and spots in the right eye was not reported. The reporter assessed the causality of the event AMN as related to the suspect vaccine (possibility of the influenza vaccination).
Age: 29.0
Sex: U
Vaccine: FLU3, TDAP
Symptoms: Syncope
Clinical narrative: Fainted.
Age: 55.0
Sex: F
Vaccine: FLU4, VARZOS
Symptoms: Herpes zoster
Clinical narrative: Patient has broken out in shingles lesions.
Age: 69.0
Sex: F
Vaccine: FLU3, VARZOS
Symptoms: Asthenia, Blood glucose normal, Dizziness, Hyperhidrosis
Clinical narrative: Pt given SHINGRIX at 10:20am. Pt. advised due to 1st dose of she should stay in clinic. Checked with PA. at 10:27am. Pt. reported lightheaded, weakness and was diaphoretic. Vital signs monitored closely.
Age: 5.0
Sex: F
Vaccine: FLU4
Symptoms: Abdominal pain, Bradycardia, Crying, Headache, Vomiting
Clinical narrative: Approximately 15-20 minutes after influenza vaccine, patient started crying and complaining of abdominal pain and headache. She vomited once. Pulse was found to be bradycardic at 52, so EPIPEN 0.15 mg was administered. She was also given BENADRYL PO 12.5 mg and 10 mg of DECADRON IV. She was given intravenous fluids with normal saline. Pulse improved to 108 after EPI. She was placed on 1 L O2 via nasal cannula for comfort only (no hypoxia). EMS was called and pt. was transported to ER for further evaluation/management.
Age: 81.0
Sex: F
Vaccine: VARZOS
Symptoms: Body temperature increased, Chills, Fatigue
Clinical narrative: Temp 101 degrees F, chills, fatigue for 24 hours without other cause.
Age: 10.0
Sex: F
Vaccine: FLU4
Symptoms: Arthralgia, C-reactive protein normal, Culture throat, Erythema, Full blood count normal
Clinical narrative: Patient developed pain inboth knees on 11/12/2018. 1 week later, on 11/19/18, developed moderate edema and pain in all joints of both feet and hands and also in both ankles and wrists. No fever. Developed erythematous blanching flat target lesions in both legs, trunk, arms and face. Seen at the office on 11/19/2018: Started on Prednisone 40 mg PO QS x 5 days. Arthralgias and edema of joints resolved after 2 days. Rash seemed to be slightly better. Developed acute hives all over body on 11/23/18 with no other symptoms: started on ALLEGRA which helped with rash. Throat Cx positive for Group A strep: started on pen V K on 11/24/18.
Age: 10.0
Sex: F
Vaccine: FLU4
Symptoms: Metabolic function test normal, Oedema, Rash, Red blood cell sedimentation rate normal, Skin lesion
Clinical narrative: Patient developed pain inboth knees on 11/12/2018. 1 week later, on 11/19/18, developed moderate edema and pain in all joints of both feet and hands and also in both ankles and wrists. No fever. Developed erythematous blanching flat target lesions in both legs, trunk, arms and face. Seen at the office on 11/19/2018: Started on Prednisone 40 mg PO QS x 5 days. Arthralgias and edema of joints resolved after 2 days. Rash seemed to be slightly better. Developed acute hives all over body on 11/23/18 with no other symptoms: started on ALLEGRA which helped with rash. Throat Cx positive for Group A strep: started on pen V K on 11/24/18.
Age: 10.0
Sex: F
Vaccine: FLU4
Symptoms: Streptococcus test positive, Urine analysis normal, Urticaria
Clinical narrative: Patient developed pain inboth knees on 11/12/2018. 1 week later, on 11/19/18, developed moderate edema and pain in all joints of both feet and hands and also in both ankles and wrists. No fever. Developed erythematous blanching flat target lesions in both legs, trunk, arms and face. Seen at the office on 11/19/2018: Started on Prednisone 40 mg PO QS x 5 days. Arthralgias and edema of joints resolved after 2 days. Rash seemed to be slightly better. Developed acute hives all over body on 11/23/18 with no other symptoms: started on ALLEGRA which helped with rash. Throat Cx positive for Group A strep: started on pen V K on 11/24/18.
Age: 81.0
Sex: M
Vaccine: VARZOS, VARZOS
Symptoms: Injection site reaction, Rash vesicular
Clinical narrative: Patient presented with a blistering rash on the left arm beneath the deltoid. Rash appeared 2 days following vaccine. Patient is scheduled to see his PCP 11/27/18 at 8:30AM.
Age: 81.0
Sex: M
Vaccine: VARZOS, VARZOS
Symptoms: Injection site erythema, Injection site pruritus, Injection site reaction, Rash vesicular
Clinical narrative: Patient presented with a blistering rash on the left arm beneath the deltoid. Rash appeared 2 days following vaccine. Patient is scheduled to see his PCP 11/27/18 at 8:30AM.
Age: 69.0
Sex: F
Vaccine: FLU3
Symptoms: Pyrexia, Tremor, Urinary incontinence
Clinical narrative: Patient reported loss of bladder control, shaking, fever over 100 degrees. Pt did not report until the next day by which time the pt felt better. Dr. did tell her she could take BENADRYL.
Age: 64.0
Sex: F
Vaccine: PNC13
Symptoms: Erythema, Pruritus
Clinical narrative: About 1 1/2 hrs after the vaccination was administered she became itchy, and red from the waist up.
Age: 72.0
Sex: M
Vaccine: FLUA3
Symptoms: Immediate post-injection reaction, Injected limb mobility decreased, Pain, Pain in extremity
Clinical narrative: Patient states pain immediately after vaccine given. "Most painful" flu shot ever. Pain and decreased range of left arm. Patient feels immunization too high on arm.
Age: 68.0
Sex: M
Vaccine: PPV
Symptoms: Injection site pain
Clinical narrative: Patient experienced constant pain at the site of injection.
Age: 57.0
Sex: F
Vaccine: VARZOS
Symptoms: Abdominal pain upper, Diarrhoea, Headache, Hyperhidrosis, Pyrexia
Clinical narrative: After vaccine, pt hands started getting sweaty, pt also had a headache, stomach cramps and fever. Symptoms improving - only diarrhea currently.